Nuclear Reaction Dynamics for Medical Radionuclide Production

Medical radionuclides are produced through carefully controlled nuclear reactions in which charged particles or neutrons interact with target nuclei to yield unstable isotopes for imaging and therapy. The reaction dynamics involve selection of projectile type (commonly protons or deuterons), beam energy and current, target material composition and isotopic enrichment, and post-irradiation chemical separation. Detailed knowledge of reaction cross-sections as a function of energy underpins efficient yield optimisation and minimises co-production of unwanted species. Cyclotron-based production has become widespread for positron emitters and therapeutic β–emitters, offering decentralised supply to hospitals. Advances in targetry, automated purification systems and nuclear data evaluation have improved radionuclidic purity, specific activity and reproducibility. These improvements enable the routine manufacture of established isotopes such as ⁶⁴Cu, ⁸⁹Zr or ¹⁷⁷Lu, and facilitate the exploration of novel radionuclides with longer half-lives or alternative decay modes. A thorough understanding of reaction pathways and beam–target interactions is essential to translating nuclear reaction studies into clinical radiopharmaceuticals with demonstrable safety and efficacy.

Research from Nature Portfolio

Recent studies have demonstrated optimisation of enriched chromium targets for the cyclotron production of ⁵²Mn. Transitioning from natural chromium to enriched ⁵²Cr targets and developing electroplated Cr(III) targetry enabled recyclable target assemblies and achieved over 94 % recovery of high-purity ⁵²Mn following improved solid-phase purification. Separately, the production and in vivo characterisation of ⁵¹MnCl₂ has been refined on low-energy medical cyclotrons. Electrodeposited enriched ⁵⁴Fe targets yielded sufficient ⁵¹Mn for dynamic PET studies, with rapid blood clearance and stable organ uptake in murine models. Dosimetry extrapolations predict clinical feasibility, marking ⁵¹Mn as a promising short-lived tracer for calcium-channel imaging.

Nuclear Reaction Dynamics for Medical Radionuclide Production publication trend

The graph below shows the total number of articles in nuclear reaction dynamics for medical radionuclide production across all publications each year (not limited to Nature Index journals).

Technical terms

Cross-section: A measure of the probability that a specific nuclear reaction will occur under given projectile energy conditions.

Cyclotron: A circular particle accelerator that produces charged-particle beams for inducing nuclear reactions in target materials.

Radionuclide: An unstable isotope that undergoes radioactive decay, emitting particles or photons used in diagnostic imaging or therapy.

Deuteron: The nucleus of deuterium, consisting of one proton and one neutron, employed as a projectile to induce nuclear reactions.

Radionuclidic purity: The proportion of the desired radionuclide relative to all radioactive contaminants in a final product.

Theranostics: A combined approach that utilises matched radionuclides for both diagnostic imaging and targeted radionuclide therapy.

References

1. Cyclotron-Based Production of 67Cu for Radionuclide Theranostics via the 70Zn(p,α)67Cu Reaction. Pharmaceuticals (2023).
2. Optimization of Deuteron Irradiation of 176Yb for Producing 177Lu of High Specific Activity Exceeding 3000 GBq/mg. Molecules (2023).
3. Natural and enriched Cr target development for production of Manganese-52. Scientific Reports (2023).
4. Preparation and in vivo characterization of 51MnCl2 as PET tracer of Ca2+ channel-mediated transport. Scientific Reports (2017).
5. Copper radionuclides for theranostic applications: towards standardisation of their nuclear data. A mini-review. Frontiers in Chemistry (2023).